Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ Mitsubishi Materials Aktie stürzt wegen geplanter Wandelanleihe ab (Investing.com DE) +++ MITSUBISHI MATERIALS Aktie -6,96%

MYRIAD GENETICS Aktie

 >MYRIAD GENETICS Aktienkurs 
5.145 EUR    (TradegateBSX)
Ask: 5.234 EUR / 958 Stück
Bid: 5.056 EUR / 992 Stück
Tagesumsatz: 0 Stück
Realtime Kurs von 7:30 bis 22 Uhr!
Aktie über LYNX handeln
>MYRIAD GENETICS Performance
1 Woche: -0,4%
1 Monat: +35,0%
3 Monate: +23,5%
6 Monate: -10,7%
1 Jahr: +10,6%
laufendes Jahr: -4,1%
>MYRIAD GENETICS Aktie
Name:  MYRIAD GENETICS DL-,01
Land:  USA
Sektor:  Gesundheit
ISIN/ Wkn:  US62855J1043 / 897518
Symbol/ Ticker:  MYD (Frankfurt) / MYGN (NASDAQ)
Kürzel:  FRA:MYD, ETR:MYD, MYD:GR, NASDAQ:MYGN
Index:  -
Webseite:  https://myriad.com/
Profil:  Myriad Genetics Inc. is a biotechnology company specializing in the development and commercialization of genetic tests that assess risk for cancer and other hereditary conditions. The company is renowned for its pioneering efforts in molecular diagno..
>Volltext..
Marktkapitalisierung:  499.32 Mio. EUR
Unternehmenswert:  574.96 Mio. EUR
Umsatz:  726.82 Mio. EUR
EBITDA:  -11.66 Mio. EUR
Nettogewinn:  -350.61 Mio. EUR
Gewinn je Aktie:  -3.78 EUR
Schulden:  185.43 Mio. EUR
Liquide Mittel:  109.07 Mio. EUR
Operativer Cashflow:  2.1 Mio. EUR
Bargeldquote:  0.96
Umsatzwachstum:  -6.62%
Gewinnwachstum:  -269.28%
Dividende je Aktie:  -
Dividendenrendite:  -
Dividendenschätzung:  -
Insiderhandel 1 Insider verkaufte innerhalb der letzten 30 Tage Aktien im Wert von 58.508 Euro.
Suchwörter:  MYRIAD GENETICS
Letzte Datenerhebung:  09.07.26
>Kennzahlen
Aktien/ Unternehmen:
Aktien: 94.45 Mio. St.
Frei handelbar: 93.02%
Rückkaufquote: -0.58%
Mitarbeiter: 2700
Umsatz/Mitarb.: 0.27 Mio. EUR
Analysten:
Analystenrating: Neutral
Kursziel: 8.7%
Bewertung:
KGV: -
KGV lG: 95.81
KUV: 0.68
KBV: 1.66
PEG-Ratio: -
EV/EBITDA: -
Rentabilität:
Bruttomarge: 66.14%
Gewinnmarge: -48.24%
Operative Marge: -7.73%
Managementeffizenz:
Gesamtkaprendite: -47.61%
Eigenkaprendite: -76.73%
>Peer Group
Gesundheit, Onkologie/ Krebs- Behandlung, Zell- & Gentherapie/ Gentechnik/ Erbkrankheiten
 
23.06.26 - 15:09
Myriad Genetics Expands Availability of Precise MRD™ for Colorectal, Renal and Breast Cancers, Supported by New Publication (GlobeNewswire EN)
 
Publication of MONITOR-Breast study marks latest milestone for clinical validity of Precise MRD Publication of MONITOR-Breast study marks latest milestone for clinical validity of Precise MRD...
10.06.26 - 00:01
Insiderhandel: Aufsichtsrat verkauft Aktien von Myriad Genetics im Wert von 66843 USD (Insiderkauf)
 
Kumar, Rashmi - Aufsichtsrat - Tag der Transaktion: 2026-06-08...
09.06.26 - 17:30
Should You Add Myriad Genetics Stock to Your Portfolio Right Now? (Zacks)
 
MYGN is gearing up with oncology testing and steady product launches, backed by sound solvency, though foreign-exchange swings could weigh on results....
02.06.26 - 15:09
Myriad Genetics Names Raj Jampa as New Chief Technology Officer (GlobeNewswire EN)
 
Myriad Genetics announces the appointment of Raj Jampa as chief technology officer (CTO)....
28.05.26 - 16:45
Is MYGN Stock a Buy at 0.4x Sales? What Investors Should Weigh (Zacks)
 
Myriad Genetics trades near 0.4x sales as investors weigh cheap valuation against 2026 launch execution and uneven segment performance....
28.05.26 - 16:45
Myriad Genetics′ Upcoming Prolaris + AI Test Debut May Lift Its Stock (Zacks)
 
MYGN plans to launch its Prolaris + AI Test this month, combining biomarker data and AI pathology to personalize prostate cancer surveillance....
27.05.26 - 15:09
Myriad Genetics Highlights Data Showing Broad Clinical Utility of Precise MRD Assay at 2026 ASCO Annual Meeting (GlobeNewswire EN)
 
Myriad Genetics Highlights Data Showing Broad Clinical Utility of Precise MRD Assay at 2026 ASCO Annual Meeting...
26.05.26 - 22:09
Myriad Genetics Launches Prolaris® + AI, the First Prostate Cancer Test to Combine Genomics and Digital Pathology Artificial Intelligence (AI) (GlobeNewswire EN)
 
Myriad Genetics Launches Prolaris® + AI, the First Prostate Cancer Test to Combine Genomics and Digital Pathology Artificial Intelligence...
15.05.26 - 17:03
Actress Jackie Tohn Got Results Nobody Wants But They May Have Saved Her Life (GlobeNewswire EN)
 
Myriad Genetics joins forces with Nobody Wants This actress Jackie Tohn...
15.05.26 - 02:02
Insiderhandel: Aufsichtsrat kauft Aktien von Myriad Genetics im Wert von 27638 USD (Insiderkauf)
 
Bisaro, Paul - Aufsichtsrat - Tag der Transaktion: 2026-05-14...
07.05.26 - 22:09
Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences (GlobeNewswire EN)
 
Myriad Genetics will participate in The BofA Securities 2026 Health Care Conference and Goldman Sachs 47th Annual Global Healthcare Conference....
06.05.26 - 20:24
Myriad Genetics in record sell-off after Q1 miss (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
06.05.26 - 04:00
Myriad Genetics (MYGN) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
 
Myriad (MYGN) delivered earnings and revenue surprises of -56.52% and -1.09%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?...
06.05.26 - 00:06
Myriad Genetics: Gemischte Ergebnisse für Q1 2026 – Prognosen verfehlt, aber Wachstum in Kernsegmenten (Investing.com DE)
 
Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...
30.04.26 - 15:09
Myriad Genetics National Survey: 88% of Patients with Depression and/or Anxiety Would Feel More Confident with a Personalized Mental Health Care Plan (GlobeNewswire EN)
 
The latest GeneSight® Mental Health Monitor from Myriad Genetics reveals that Americans feel mental health treatment isn't designed with them in mind....
28.04.26 - 22:09
Myriad Genetics to Release First Quarter 2026 Financial Results on May 5, 2026 (GlobeNewswire EN)
 
Myriad Genetics will hold its first quarter 2026 earnings conference call at 4:30 pm ET on Tuesday, May 5, 2026. Webcast at investor.myriad.com....
28.04.26 - 17:31
Analysts Estimate Myriad Genetics (MYGN) to Report a Decline in Earnings: What to Look Out for (Zacks)
 
Myriad (MYGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations....
16.04.26 - 15:18
Myriad Genetics to Deliver Six Abstracts, Including Two Podiums, at AACR 2026 (GlobeNewswire EN)
 
Myriad Genetics will share six abstracts, including two podium presentations, at the American Association for Cancer Research (AACR) Annual Meeting....
14.04.26 - 15:18
Myriad Genetics Expands Access for MyChoice Test to Prostate Cancer Patients in Japan (GlobeNewswire EN)
 
SALT LAKE CITY, April 14, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved the use of the MyChoice® Test for prostate cancer patients as a companion diagnostic for Lynparza® (olaparib). With this approval, clinicians can now order the MyChoice Test to determine homologous recombination deficiency (HRD) status for patients with ovarian cancer, and BRCA1/2 status for breast and prostate cancers....
09.04.26 - 15:18
Myriad Genetics Underscores Commitment to Cancer Care Continuum with New Data Presentations at SGO Annual Meeting (GlobeNewswire EN)
 
Myriad will share new data at the Society of Gynecologic Oncology (SGO) Annual Meeting April 10-13, including two oral presentations and two posters....
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Bei einem großen Dichter hat man das Gefühl, als ob Dinge emportauchen, die im Chaos stecken geblieben sind. - Christian Friedrich Hebbel
>Aktienauflistung | >Aktienscreener | >Aktienkennzahlen | >Anleihen | >ETFs | >Fonds | >Branchen | >Länder | >Themen | >Redaktionen
Partner:    >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!